Removab (catumaxomab)
- Region
- 🇪🇺 EU
- Active substance
- catumaxomab
- Company
- Neovii Biotech GmbH
- Status
- Withdrawn
- Therapeutic area
- Ascites; Cancer
- EU approval
- Mon 20 Apr 2009
- Application
- EMEA/H/C/000972
- ATC
- L01XC09
- Official record
- www.ema.europa.eu
Indication
Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Korjuny Authorised · Atnahs Pharma Netherlands B.V.
Follow Removab
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.